X4 Pharmaceuticals (XFOR) Change in Acquisitions & Divestments (2023 - 2026)

X4 Pharmaceuticals (XFOR) has reported Change in Acquisitions & Divestments for 4 consecutive years, with $4.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Change in Acquisitions & Divestments fell 85.8% year-over-year to $4.0 million; the trailing twelve-month figure through Jun 2026 stood at $57.9 million (down 2.54% YoY), and the FY2025 full-year result was $74.5 million, up 181.82% from the prior year.
• Change in Acquisitions & Divestments declined to $4.0 million in Q2 2026 per XFOR's latest filing, from $19.3 million in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $28.2 million in Q2 2025 and bottomed at $1.0 million in Q3 2023.
• Historically, Change in Acquisitions & Divestments has averaged $10.5 million across 4 years, with a median of $8.5 million in 2024.
• The sharpest annual moves came in 2024 and 2026: Change in Acquisitions & Divestments surged 1320.0% in 2024, then slumped 85.8% in 2026.
• Over 4 years, Change in Acquisitions & Divestments stood at $1.0 million in 2023, then soared by 1320.0% to $14.2 million in 2024, then soared by 32.04% to $18.8 million in 2025, then sank by 78.67% to $4.0 million in 2026.
• According to Business Quant data, Change in Acquisitions & Divestments over the past three periods registered $4.0 million, $19.3 million, and $18.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.